Lepu Biopharma
Biopharmaceutical company developing immuno-oncology antibodies, antibody-drug conjugates and oncolytic-virus therapies.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Squamous Cell Carcinoma of the Head and Neck
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaPhase 3 · Recruiting · Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic CancerPhase 3 · Not Yet Recruiting · Advanced Pancreatic Cancer
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsPhase 1 · Recruiting · Advanced Solid Tumors
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell CarcinomaPhase 2 · Recruiting · Head and Neck Squamous Cell Carcinoma
A Study of MRG006A in the Treatment of Patients With Advanced Solid TumorsPhase 1 · Recruiting · Advanced Solid Tumors
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/lepu-biopharma/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.